Frontotemporal dementia - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Frontotemporal dementia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Frontotemporal dementia: Overview
Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer’s disease in the 45–64 age group.
'Frontotemporal dementia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Frontotemporal dementia Emerging Drugs
Further product details are provided in the report……..
Frontotemporal dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:
Frontotemporal dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.
Frontotemporal dementia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Frontotemporal dementia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Frontotemporal dementia: Overview
Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer’s disease in the 45–64 age group.
'Frontotemporal dementia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.
This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Frontotemporal dementia Emerging Drugs
- PR006: Prevail Therapeutics
- AL001: Alector
Further product details are provided in the report……..
Frontotemporal dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Frontotemporal dementia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Frontotemporal dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.
Frontotemporal dementia Report Insights
- Frontotemporal dementia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Frontotemporal dementia drugs?
- How many Frontotemporal dementia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal dementia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal dementia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Frontotemporal dementia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Alector
- Prevail Therapeutics
- Passage Bio, Inc.
- TauRx Pharmaceuticals
- Wave Life Sciences Ltd.
- CAMP4 Therapeutics
- Coya Therapeutics
- SOLA Biosciences
- AcuraStem
- Denali Therapeutics
- Wave Life Sciences
- Neurimmune
- Biogen
- Asceneuron SA
- Libra Therapeutics
- Muna Therapeutics
- Alkermes
- DEEP GENOMICS
- Sangamo Therapeutics
- LOCANABIO
- Arkuda Therapeutics
- AZTherapies
- Yumanity
- Autifony Therapeutics
- Prothena
- PR006
- AL 001
- PBFT02
- TRx-0237
- WVE-004
- EXO-050
- SOL 257
- AS 201
- AS 202
- DNL593
- NI308
- NI205
Introduction
Executive Summary
Frontotemporal dementia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
AL001: Alector
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
PR006: Prevail Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EXO-050: Coya Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Frontotemporal dementia Key Companies
Frontotemporal dementia Key Products
Frontotemporal dementia- Unmet Needs
Frontotemporal dementia- Market Drivers and Barriers
Frontotemporal dementia- Future Perspectives and Conclusion
Frontotemporal dementia Analyst Views
Frontotemporal dementia Key Companies
Appendix
Executive Summary
Frontotemporal dementia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
AL001: Alector
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
PR006: Prevail Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
EXO-050: Coya Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Frontotemporal dementia Key Companies
Frontotemporal dementia Key Products
Frontotemporal dementia- Unmet Needs
Frontotemporal dementia- Market Drivers and Barriers
Frontotemporal dementia- Future Perspectives and Conclusion
Frontotemporal dementia Analyst Views
Frontotemporal dementia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Frontotemporal dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Frontotemporal dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Frontotemporal dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Frontotemporal dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products